Abstract：
CONCLUSIONS: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
OBJECTIVE: To describe the application of the Plan-Do-Study-Act quality improvement framework in the development, implementation, and evaluation of a novel pharmacy practice model in ambulatory oncology.
CONCLUSIONS: Four iterations of the Plan-Do-Study-Act framework were completed to develop a patient-facing, pharmacist-led ambulatory oncology clinic program. The clinic provided care to patients with prostate cancer on oral anticancer therapy. Metrics were collected throughout all stages of development to inform target processes for improvement. The pharmacist saw 136 patients between July 2019 and January 2023, resulting in 464 total encounters. The pharmacist provided clinical interventions and counseling to patients newly starting on oral anticancer therapy and those established on therapy using a longitudinal model of care.
CONCLUSIONS: Application of the Plan-Do-Study-Act quality improvement framework to a novel pharmacy practice model supported the development, evaluation, and sustainability of a pharmacist-led ambulatory oncology clinic providing care to patients with prostate cancer on oral anticancer therapy.
OBJECTIVE: To describe the application of the Plan-Do-Study-Act quality improvement framework in the development, implementation, and evaluation of a novel pharmacy practice model in ambulatory oncology.
CONCLUSIONS: Four iterations of the Plan-Do-Study-Act framework were completed to develop a patient-facing, pharmacist-led ambulatory oncology clinic program. The clinic provided care to patients with prostate cancer on oral anticancer therapy. Metrics were collected throughout all stages of development to inform target processes for improvement. The pharmacist saw 136 patients between July 2019 and January 2023, resulting in 464 total encounters. The pharmacist provided clinical interventions and counseling to patients newly starting on oral anticancer therapy and those established on therapy using a longitudinal model of care.
CONCLUSIONS: Application of the Plan-Do-Study-Act quality improvement framework to a novel pharmacy practice model supported the development, evaluation, and sustainability of a pharmacist-led ambulatory oncology clinic providing care to patients with prostate cancer on oral anticancer therapy.
摘要：
结论：为了加快文章的发表，AJHP在接受后尽快在线发布手稿。接受的手稿经过同行评审和复制编辑，但在技术格式化和作者打样之前在线发布。这些手稿不是记录的最终版本，将在以后替换为最终文章（按照AJHP样式格式化并由作者证明）。
目的：描述Plan-Do-Study-Act质量改进框架在开发中的应用，实施，并评估了一种新型的门诊肿瘤学药学实践模式。
结论：完成了计划-做-研究-法案框架的四次迭代，以开发面向患者的，药剂师主导的门诊肿瘤诊所计划。诊所为前列腺癌患者提供口服抗癌治疗的护理。在开发的所有阶段都收集了指标，以告知目标过程以进行改进。药剂师在2019年7月至2023年1月期间收治了136名患者，共接触464例。药剂师为新开始口服抗癌治疗的患者以及使用纵向护理模型建立治疗的患者提供临床干预和咨询。
结论：将Plan-Do-Study-Act质量改进框架应用于一种新的药学实践模式，评估，以及由药剂师领导的门诊肿瘤诊所的可持续性，为前列腺癌患者提供口服抗癌治疗。
目的：描述Plan-Do-Study-Act质量改进框架在开发中的应用，实施，并评估了一种新型的门诊肿瘤学药学实践模式。
结论：完成了计划-做-研究-法案框架的四次迭代，以开发面向患者的，药剂师主导的门诊肿瘤诊所计划。诊所为前列腺癌患者提供口服抗癌治疗的护理。在开发的所有阶段都收集了指标，以告知目标过程以进行改进。药剂师在2019年7月至2023年1月期间收治了136名患者，共接触464例。药剂师为新开始口服抗癌治疗的患者以及使用纵向护理模型建立治疗的患者提供临床干预和咨询。
结论：将Plan-Do-Study-Act质量改进框架应用于一种新的药学实践模式，评估，以及由药剂师领导的门诊肿瘤诊所的可持续性，为前列腺癌患者提供口服抗癌治疗。
